Skip to main content
. 2020 Nov 24;8(2):e001435. doi: 10.1136/jitc-2020-001435

Figure 4.

Figure 4

Intermediate dose of regorafenib shows efficacy when combined with antiprogrammed cell death protein 1 (anti-PD1) blockade in the RIL-175 mouse model of advanced hepatocellular carcinoma (HCC). (A) Example of tumor implantation and treatment schedule for survival studies in HCC models. (B, C) Survival experiment data from RIL-175 orthotopic mouse model. Tumor growth was significantly delayed in the group treated with a combination of regorafenib 10 mg/kg and anti-PD1 antibody (aPD1) compared with the other groups (n=10–13 mice) (B); moreover, this combination significantly prolonged overall survival (C). (D) Survival experiment data from HCA-1 highly metastatic orthotopic mouse model. Mice treated with combination with R10+P show a non-significant trend for increased survival versus control (HR=0.48, p=0.075) (n=11–13 mice). (E) Tumor growth is delayed after combination of R10+P in a spontaneous HCC model using Mst1–/–Mst2F/– mice (n=6–9 mice). (F) Treatment with regorafenib (10 mg/kg daily, R10) alone or in combination with anti-PD-1 therapy shows no benefit in survival (Kaplan-Meier survival distributions) compared with control. *P<0.05, **p<0.01, ***p<0.001. C, control; P, anti-PD1; R10, regorafenib 10 mg/kg daily; R10+P, regorafenib 10 mg/kg+anti-PD1. Error bars, SEM.